Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Down 6.3% – What’s Next?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) were down 6.3% during mid-day trading on Thursday. The company traded as low as $27.77 and last traded at $27.8650. 161,127 shares traded hands during trading, a decline of 32% from the average daily volume of 238,595 shares. The stock had previously closed at $29.74.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Raymond James Financial started coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 price target on the stock. JonesTrading initiated coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, September 14th. Needham & Company LLC began coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They set a “buy” rating and a $56.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Price Performance

The company has a market capitalization of $732.56 million, a price-to-earnings ratio of -0.20 and a beta of -0.29. The firm’s fifty day simple moving average is $32.09.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, research analysts predict that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics in the second quarter worth $3,610,000. Renaissance Technologies LLC grew its holdings in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of Sensei Biotherapeutics during the first quarter valued at $4,188,000. Finally, Vivo Capital LLC acquired a new position in Sensei Biotherapeutics during the first quarter valued at $22,758,000. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.